Co-workers

In current position since 2019, employed since 2011.

Education: Secondary school economics 1989, graduate in accounting 1999, certified controller 2021.

Experience and prior assignments: Carina Eldh has more than 20 years of experience in accounting, auditing and taxation and has previously held positions at KPMG and other auditing and advisory firms, the Swedish Tax Agency and Öresundskraft.

Other current assignments: –

Born: 1970

Holdings: 9,900 shares* and 20,000 warrants**.

In current position since 2023.

Education: M.Sc. in Pharmacy in 2000 from the Faculty of Pharmaceutical Sciences, University of Copenhagen.

Experience and prior assignments: René Egebro has more than 23 years of experience from senior positions in Chemical, Manufacturing & Control from pre-clinical development to late-stage clinical development. René has a broad experience as Senior Director and CMC outsourcing manager in managing International CMOs for the development, manufacture, formulation and analysis of cGMP Drug Substances and Drug Products. René has held positions at Novo Nordisk, Lundbeck, NeuroSearch and several small biotech leading CMC development, ensuring progress and oversight of multiple development programs, providing strategic advice on CMC development, and representing the company in front of FDA and other regulatory authorities.

Other current assignments: –

Born: 1974

Holdings: –

In current position since 2024

Education: Ph. D. in Organic Chemistry from Uppsala university 1998

Experience and prior assignments: Fredrik has 25 years of experience in the pharmaceutical industry, most recently as VP and Director of Medicinal Chemistry at Galecto Biotech, where he developed several drug candidates, including the first orally available galectin-3 inhibitor, GB1211, currently in phase 2 studies. He began his career at Astra in 1994 and has held various roles at Astra/AstraZeneca, contributing to several clinical candidates in cardiovascular medicine, including ticagrelor. Fredrik has 38 academic publications, 26 patent applications, and collaborates with Lund University, co-supervising PhD students and giving lectures in medicinal chemistry.

Other current assignments: Member of the board and CEO of BIOZET AB.

Born: 1968

Holdings: –

In current position since 2022.

Education: Master of Medicine in Pharmaceutical Bioscience, Gothenburg University, PhD in Medical Inflammation Research, Lund University.

Experience and prior assignments: Malin Hultqvist Hopkins has more than 15 years of experience in R&D and early drug discovery. She has held several operational roles at Redoxis AB, including Project Leader Drug Discovery, Director of CRO Studies and since 2016 she is the CEO of the company. Redoxis offers preclinical services. Malin holds a genuine experience in immunology and preclinical models of inflammation and autoimmunity.

Other current assignments: Board member of Redoxis AB and ProNoxis AB.

Born: 1979

Holdings: 7,950 shares*.

In current position since 2023.

Education: Ph.D. in Biochemistry/Immunology 1998 from Imperial College, London.

Experience and prior assignments: Wayne Russell has more than 18 years of experience from the pharmaceutical industry, covering all aspects of the R&D pipeline from target identification to clinical development and external innovation evaluation. He has held positions at AstraZeneca, LEO Pharma and Zealand Pharma, working in dermatology, gastrointestinal and metabolic, inflammation, and respiratory therapeutic areas. More recently Wayne worked in the Innovation office at Lund University.

Other current assignments: –

Born: 1972

Holdings: 21,011 warrants**.

In current position since 2023.

Education: Master of Medical Science in Medical Biology, Linköping University, studies in clinical drug development at Uppsala University.

Experience and prior assignments: Anna-Mia has more than 10 years of experience within the quality area. She started her career at a small pharmaceutical company as quality manager and later she joined the Swedish Clinical Team at the global pharmaceutical company Novo Nordisk. During her years at Novo Nordisk she gained a broad experience within clinical operations with focus on Phase III clinical trials in several indications and therapy areas. She has previously held the position as project manager at the Coordination Council of Neurology, Region Västra Götaland.

Other current assignments: –

Born: 1984

Holdings: 21,011 warrants**.